Gibo Takahiko, Sekiguchi Nodoka, Gomi Daisuke, Noguchi Takuro, Fukushima Toshirou, Kobayashi Takashi, Ozawa Takesumi, Yamada Shin-Ichi, Koizumi Tomonobu
Department of Dentistry and Oral Surgery, Shinshu University School of Medicine, Matsumoto, Nagano 390-8621, Japan.
Department of Comprehensive Cancer Therapy, Shinshu University School of Medicine, Matsumoto, Nagano 390-8621, Japan.
Mol Clin Oncol. 2019 Aug;11(2):111-115. doi: 10.3892/mco.2019.1875. Epub 2019 Jun 10.
Herein we report two cases of advanced and/or metastatic salivary duct carcinoma that relapsed after standard first-line chemotherapy. As overexpression of human epidermal growth factor receptor 2 (HER2) (3+) was observed by immunohistochemistry, the patients were treated with trastuzumab plus paclitaxel. One patient showed a complete response lasting over 2.5 years after the commencement of therapy; however, the other patient had no response to trastuzumab combined therapy. Dual fluorescence hybridization was performed after the initiation of chemotherapy; the first case was positive for HER2 gene amplification, while the second case was negative. Our experiences suggest that therapy with HER2 blockers should be considered as options for treatment of HER2-positive salivary duct carcinoma. However, HER2 protein overexpression and gene amplification should be investigated further as therapeutic biomarkers.
在此，我们报告两例晚期和/或转移性涎腺导管癌患者，他们在接受标准一线化疗后复发。免疫组化检测发现人表皮生长因子受体2（HER2）呈过表达（3+），这两名患者接受了曲妥珠单抗联合紫杉醇治疗。一名患者在治疗开始后出现了持续超过2.5年的完全缓解；然而，另一名患者对曲妥珠单抗联合治疗无反应。化疗开始后进行了双色荧光杂交；第一例HER2基因扩增呈阳性，而第二例为阴性。我们的经验表明，HER2阻断剂治疗应被视为HER2阳性涎腺导管癌的治疗选择。然而，HER2蛋白过表达和基因扩增作为治疗生物标志物仍需进一步研究。
